Non-small cell lung cancer (NSCLC)
Non-small cell lung cancer accounts for 85 to 88% of lung cancers. The relative five-year overall survival of this disease is 15.6%. For most patients, this cancer is discovered at an advanced stage, making it difficult to treat. In part because of its poor prognosis, NSCLC is considered as a major public health issue.
Tedopi® is developed for patients who express the HLA-A2 marker. For NSCLC, the presence of this marker is considered an aggravating risk factor at an advanced stage. Approximately 45% of the global population, and of patients with this disease, possess the HLA-A2 marker (also called “HLA-A2+”). Tedopi® may therefore potentially address nearly 84,000 patients in the USA, 134,000 in Europe and 258,000 in China.
Despite the various therapies available today (surgery, radiotherapy, chemotherapy, targeted therapy), the relative survival rate of these patients at metastatic stage is only about 1% for those with lung cancer NSCLC. The need for effective and well tolerated treatments remains strong.
Tedopi® by OSE Immunotherapeutics, a new activation immunotherapy developed for NSCLC cancer
Tedopi®, developed for the treatment of non-small cell lung cancer (NSCLC), works by stimulating the body’s T cytotoxic “killer” cells and reprogramming them to spot malignant cells for elimination. These are the steps that encompass the immunosurveillance process.
Tedopi® is a patented combination of neo-10 epitopes selected and optimized from five tumorous antigens. These 10 neo-epitopes generate a specific response from the T cytotoxic cells against the malignant cells which express at least one of these tumorous antigens. The selected epitopes are chemically optimized and combined to avoid any phenomenon of immune tolerance. Tedopi® is a personalized treatment for HLA-A2+ patients.
The goal is to stabilize the development of the disease and to extend patients’ lives.
Data generated from a Phase 2 clinical trial showed that Tedopi® was effective in treating NSCLC, by increasing the relative survival rate.
More about clinical trials of Tedopi ® and the results recorded